News

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Why Summit Therapeutics Stock Soared 8% Higher Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...
pharmaphorum2d
Summit climbs on rumour of $15bn AstraZeneca interest
Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...
2 Soaring Stocks With More Upside Potential to Buy and Hold
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Forbes India5d
Maky Zangenah: Taking cancer drug maker Summit Therapeutics to staggering heights
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
MarketWatch5d
Revolution Medicines, Summit Therapeutics Partner to Evaluate Combination of Treatments in Certain Cancers
Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood ...